Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Temsirolimus

FDA-approved product (solution, intravenous), marketed as Temsirolimus, Torisel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Temsirolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Clear cell renal carcinoma
  • Mantle cell lymphoma
  • Neoplasm
  • Renal cell carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Mammalian target of rapamycin (mtor) kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA70.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Temsirolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Temsirolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy

    NCT07443826 · start 2026-06-01

    Registered record
    Registry ID
    NCT07443826
    Conditions
    Age-related Muscle Decline
    Interventions
    AAV9-Follistatin gene therapy; VEGF Plasmid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2026-06-01
    Completion
    2028-06-30
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAge-related Muscle Decline
    InterventionAAV9-Follistatin gene therapy; VEGF Plasmid
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19

    NCT06960928 · start 2025-04-18

    Registered record
    Registry ID
    NCT06960928
    Conditions
    Long COVID-19
    Interventions
    Low-dose sirolimus; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-04-18
    Completion
    2027-05-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLong COVID-19
    InterventionLow-dose sirolimus; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation

    NCT07033858 · start 2025-03-01

    Registered record
    Registry ID
    NCT07033858
    Conditions
    Kidney Transplant; Complications
    Interventions
    Rapamune Pill
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-03-01
    Completion
    2026-07-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplant; Complications
    InterventionRapamune Pill
    PhaseNot applicable
    Registry statusRecruiting

  • Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot Trial

    NCT06091332 · start 2024-01-05

    Registered record
    Registry ID
    NCT06091332
    Conditions
    Cavernous Malformations; Intracerebral Hemorrhage; Brainstem Stroke
    Interventions
    Sirolimus; Starch flake
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-01-05
    Completion
    2026-12-31
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCavernous Malformations; Intracerebral Hemorrhage; Brainstem Stroke
    InterventionSirolimus; Starch flake
    PhasePhase 2
    Registry statusRecruiting

  • The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals

    NCT06550271 · start 2023-04-25

    Registered record
    Registry ID
    NCT06550271
    Conditions
    Aging
    Interventions
    Rapamycin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-04-25
    Completion
    2023-12-15
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAging
    InterventionRapamycin
    PhaseNot recorded
    Registry statusCompleted

  • Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

    NCT05661461 · start 2022-11-23

    Registered record
    Registry ID
    NCT05661461
    Conditions
    Tumor, Solid; Tumor; Advanced Solid Tumor
    Interventions
    nab-sirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2022-11-23
    Completion
    2026-08-01
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTumor, Solid; Tumor; Advanced Solid Tumor
    Interventionnab-sirolimus
    PhasePhase 1
    Registry statusRecruiting

  • Effect of Loratadine in Lymphangioleiomyomatosis

    NCT05190627 · start 2021-11-01

    Registered record
    Registry ID
    NCT05190627
    Conditions
    Lymphangioleiomyomatosis
    Interventions
    Loratadine; Placebo 10mg/day added to rapamycin for 12 months
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-11-01
    Completion
    2023-12-30
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphangioleiomyomatosis
    InterventionLoratadine; Placebo 10mg/day added to rapamycin for 12 months
    PhasePhase 2
    Registry statusUnknown

  • Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

    NCT04177004 · start 2021-04-30

    Registered record
    Registry ID
    NCT04177004
    Conditions
    Allogeneic Hematopoietic Stem Cell Transplant Recipient; Hematopoietic and Lymphoid Cell Neoplasm
    Interventions
    Allogeneic Hematopoietic Stem Cell Transplantation; Cyclophosphamide; Etoposide; Fractionated Stereotactic Radiation Therapy; Goat Milk; Palifermin; Sirolimus; Tacrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2021-04-30
    Completion
    2026-10-27
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllogeneic Hematopoietic Stem Cell Transplant Recipient; Hematopoietic and Lymphoid Cell Neoplasm
    InterventionAllogeneic Hematopoietic Stem Cell Transplantation; Cyclophosphamide; Etoposide; Fractionated Stereotactic Radiation Therapy +4 more
    PhasePhase 1
    Registry statusActive not recruiting

  • Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia

    NCT04341675 · start 2020-04-24

    Registered record
    Registry ID
    NCT04341675
    Conditions
    COVID-19
    Interventions
    Sirolimus; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-04-24
    Completion
    2020-09-15
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionSirolimus; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and Other Susceptible Lesions

    NCT04172922 · start 2020-04-01

    Registered record
    Registry ID
    NCT04172922
    Conditions
    Vascular Anomaly
    Interventions
    Topical Sirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2020-04-01
    Completion
    2024-02-15
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVascular Anomaly
    InterventionTopical Sirolimus
    PhasePhase 1
    Registry statusTerminated

  • Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas

    NCT03696355 · start 2018-11-19

    Registered record
    Registry ID
    NCT03696355
    Conditions
    Brain and Central Nervous System Tumors
    Interventions
    GDC-0084; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-11-19
    Completion
    2022-09-04
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain and Central Nervous System Tumors
    InterventionGDC-0084; radiation therapy
    PhasePhase 1
    Registry statusCompleted

  • LAM Pilot Study With Imatinib Mesylate

    NCT03131999 · start 2018-01-23

    Registered record
    Registry ID
    NCT03131999
    Conditions
    Lymphangioleiomyomatosis
    Interventions
    Imatinib Mesylate 400Mg Capsule; Placebo - Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-01-23
    Completion
    2019-03-07
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphangioleiomyomatosis
    InterventionImatinib Mesylate 400Mg Capsule; Placebo - Capsule
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

    NCT02959918 · start 2016-10

    Registered record
    Registry ID
    NCT02959918
    Conditions
    Gout Chronic; Hyperuricemia
    Interventions
    SEL-212; SEL-037; SVP-rapamycin (SEL-110)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-10
    Completion
    2019-01
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout Chronic; Hyperuricemia
    InterventionSEL-212; SEL-037; SVP-rapamycin (SEL-110)
    PhasePhase 2
    Registry statusCompleted

  • Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

    NCT02321501 · start 2016-06-22

    Registered record
    Registry ID
    NCT02321501
    Conditions
    ALK Positive; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; ROS1 Gene Rearrangement; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IV Lung Non-Small Cell Cancer AJCC v7
    Interventions
    Ceritinib; Everolimus; Laboratory Biomarker Analysis; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2016-06-22
    Completion
    2026-12-31
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK Positive; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; ROS1 Gene Rearrangement +2 more
    InterventionCeritinib; Everolimus; Laboratory Biomarker Analysis; Pharmacological Study
    PhasePhase 1
    Registry statusActive not recruiting

  • PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

    NCT02584647 · start 2015-11-04

    Registered record
    Registry ID
    NCT02584647
    Conditions
    Sarcoma; Malignant Peripheral Nerve Sheath Tumors
    Interventions
    PLX3397; sirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2015-11-04
    Completion
    2024-10-01
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma; Malignant Peripheral Nerve Sheath Tumors
    InterventionPLX3397; sirolimus
    PhasePhase 1 / Phase 2
    Registry statusTerminated